Precigen, Inc. Common Stock (PGEN)
Precigen, Inc. is a biotechnology company focused on the development of gene and cell therapies, immunotherapies, and advanced genetic medicines. It aims to address unmet medical needs across various indications, including cancer, infectious diseases, and autoimmune disorders, through innovative platform technologies and proprietary scientific approaches.
Company News
Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.
Precigen has submitted a biologics license application to the FDA for PRGN-2012, a potential first treatment for recurrent respiratory papillomatosis. The submission is a significant step forward, as PRGN-2012 has received Breakthrough Therapy and Orphan Drug Designations from the FDA.
Read about the upcoming Wall Street events, earnings reports, conferences, and IPOs for the week ahead.
Precigen (PGEN) delivered earnings and revenue surprises of -11.11% and 30.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Penny stocks to buy according to these insiders this month. The post 10 Top Penny Stocks To Buy According To Insiders In August appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.